Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Monthly Archives: June 2016

BioNJ Report: Clinical Trials Activity in New Jersey Delivers 3,750 Jobs and $779M in Economic Output

Clinical Trial 3

Trenton, NJ, June 24, 2016BioNJ, the trade association for New Jersey’s life sciences industry, yesterday released its “Economic Impact Study of Clinical Trials Activity in New Jersey” in collaboration with Rutgers Business School and Rutgers Bloustein School of Planning and Public Policy noting that clinical trials activity in New Jersey delivers 3,750 jobs and $779 million in economic output.

The first study of its kind in New Jersey, the research brief serves as a call for efforts to increase clinical trials capacity and resources in the State and for the education of all stakeholders as to the value delivered to the healthcare system through the conduct of clinical trials. Continue reading

Congressional Bipartisan Talks on Zika Virus Break Down Ahead of July 4 Recess

Capitol Rotunda flagWashington, DC, June 23, 2016The Washington Post reports that the U.S. House of Representatives voted in the wee hours of Thursday morning to approve a $1.1 billion package to fight the Zika virus.

But the measure was the product of a deal between House and Senate Republicans and Democrats do not support it, meaning lawmakers are once again headed home without a tool aimed at fighting the Zika virus at the height of mosquito season.

Democrats abandoned negotiations on Wednesday in part because Republicans insisted that funding for the Zika measure be partially paid for by cuts to the Affordable Care Act and by shifting more than $100 million from the Ebola emergency fund, according to Democratic aides. Continue reading

Rowan and Durin Technologies Researchers Develop Alzheimer’s Detection Test

Rowan University logoGlassboro, NJ, June 23, 2016 — Anjalee Khemlani reports in NJBIZ that a team of researchers led by Robert Nagele from Rowan University has developed a blood test that uses the body’s immune response system to detect an early stage of Alzheimer’s disease.

The test was developed with a team from Rowan’s School of Osteopathic Medicine and Durin Technologies, and detects mild cognitive impairment, according to a statement from Rowan.

In a test with 236 individuals, a sensitivity and specificity rate of 100 percent was achieved for identifying subjects with the early stage of Alzheimer’s. Continue reading

Rutgers Research: Experimental Antibiotic Treats Deadly MRSA Infection

Antibiotic 1New Brunswick, NJ, June 23, 2016 — A new experimental antibiotic developed by a team of scientists at Rutgers University successfully treats the deadly MRSA infection and restores the efficacy of a commonly prescribed antibiotic that has become ineffective against MRSA.

In research published in the July issue of Antimicrobial Agents and Chemotherapy, Rutgers scientists say that the combination of their newly developed antibiotic, TXA709, with cefdinir, an antibiotic that has been on the market for almost two decades, successfully treated the MRSA infection in animals. Continue reading

House GOP to Unveil Plan to Replace Obamacare; Its Costs Are Unclear

Capitol Dome HEALTHCAREWashington, DC, June 22, 2016 — Mike DeBonis reports in The Washington Post that House Republicans today are scheduled to unveil their plan to replace President Obama’s signature health care reform law — the first such proposal in the six years since the Affordable Care Act’s passage to carry the endorsement of House GOP leadership.

The Republican plan would discard the mandates and penalties that have made Obamacare a perennial target for GOP lawmakers, according to DeBonis.

However, it comes with uncertain costs and an unknown impact on the number of insured Americans. Continue reading

NIH Panel Approves First Test of CRISPR Editing in Humans; Study to Target Three Types of Cancer

Gene editing crisprBethesda, MD, June 22, 2016The Washington Post reports that a National Institutes of Health (NIH) advisory panel yesterday approved the first human use of the gene-editing technology CRISPR, for a study designed to target three types of cancer and funded by tech billionaire Sean Parker’s new cancer institute.

The experiment, proposed by researchers at the University of Pennsylvania, would use CRISPR-Cas9 technology to modify patients’ own T cells to make them more effective in attacking melanoma, multiple myeloma and sarcoma.

The federal Recombinant DNA Advisory Committee approved the Penn proposal unanimously, with one member abstaining.  The experiment still must be approved by the Food and Drug Administration, which regulates clinical trials. Continue reading

Rutgers Supercomputer ‘Caliburn’ Ranked #2 Among Big Ten Universities, #8 Among U.S. Academic Institutions by ‘Top500’ List

Rutgers SupercomputerNew Brunswick, NJ, June 22, 2016 — The updated Top 500 ranking of world’s most powerful supercomputers ranks Rutgers’ new University’s academic supercomputer #2 among Big Ten universities, #8 among U.S. academic institutions, #49 among academic institutions globally and #165 among all supercomputers worldwide.

The Top 500 project provides a reliable basis for tracking and detecting trends in high-performance computing. Twice each year it assembles and releases a list of the sites operating the 500 most powerful computer systems in the world.

Rutgers’ new supercomputer, which is named “Caliburn,” is the most powerful system in the state. It was built with a $10 million award to Rutgers from the New Jersey Higher Education Leasing Fund.   Continue reading

NIH Launches Large Study of Pregnant Women in Areas Affected by Zika Virus

NIH in BlueBethesda, MD, June 22, 2016 — The National Institutes of Health and Fundacao Oswaldo Cruz-Fiocruz (Fiocruz), a national scientific research organization linked to the Brazilian Ministry of Health, have begun a multi-country study to evaluate the magnitude of health risks that Zika virus infection poses to pregnant women and their developing fetuses and infants.

The study is opening in Puerto Rico and will expand to several locations in Brazil, Colombia and other areas that are experiencing active local transmission of the virus.

Zika virus is spread primarily through bites from infected Aedes aegypti mosquitoes, although other forms of transmission—notably, mother-to-child and sexual transmission—also occur.  Active virus transmission currently is ongoing in 60 countries and territories. Continue reading

Target ALS Foundation Selects RUCDR Infinite Biologics

Rutgers RNew Brunswick, NJ, June 21, 2016 — The Target ALS Foundation has selected RUCDR Infinite Biologics to bank and distribute the foundation’s human stem cell lines for use by researchers in academia and industry worldwide.

A unit of Rutgers’ Human Genetics Institute of New Jersey, RUCDR is the world’s largest university-based biorepository.

Target ALS Foundation is a privately funded non-profit foundation “entirely focused on finding treatments for patients living with ALS” or amyotrophic lateral sclerosis, a fatal neurodegenerative disease known as Lou Gehrig’s disease. Continue reading

FDA Approves First Experimental Zika Vaccine to Begin Human Testing

Vaccine kidWashington, DC, June 21, 2016 — The Associated Press reports that an experimental vaccine for the Zika virus is due to begin human testing in coming weeks, after getting the green light from U.S. health officials.

Inovio Pharmaceuticals said Monday it received clearance from the Food and Drug Administration to begin early-stage safety tests of its DNA-based vaccine against the mosquito-borne virus.  That puts the company ahead of researchers at the National Institutes of Health, who have said they expect to begin testing their own DNA-based Zika vaccine by early fall.

Inovio’s vaccine is intended to prime the immune system to fight Zika by introducing genetically-engineered material that mimics the virus.  Inovio reports that animals tested with the vaccine developed antibodies and immune-system cells that attack Zika. Continue reading